Irinotecan Arrow

Irinotecan, the active ingredient in Irinotecan Arrow, is a topoisomerase I inhibitor presented as an injectable solution for intravenous use. It is employed in the treatment of metastatic colorectal cancer in adult patients, often as part of combination chemotherapy regimens designed to improve response rates and survival outcomes.

GNH USA supplies Irinotecan Arrow as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, providing reliable sourcing, regulatory documentation and cold‑chain logistics to meet the needs of clinical and procurement teams across multiple regions.

Irinotecan Arrow is indicated for colorectal cancer treatment, targeting metastatic disease.

Metastatic colorectal cancer (first‑line combination therapy): used with other agents to achieve tumor reduction and extend survival. Metastatic colorectal cancer (second‑line after fluoropyrimidine failure): provides an alternative cytotoxic option when disease progresses. Metastatic colorectal cancer (refractory disease): can be administered as monotherapy to control tumor growth.

Irinotecan Arrow may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Diarrhea: may be severe and require supportive care. - Nausea and vomiting: common gastrointestinal symptoms. - Alopecia: hair loss during treatment. - Fatigue: generalized tiredness. - Anemia: decreased red blood cell levels.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent care. - Severe colitis or ileitis: life‑threatening intestinal inflammation. - Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Hepatotoxicity: elevated liver enzymes or liver injury. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Tumor lysis syndrome: metabolic disturbances from rapid tumor cell breakdown.

Prior to initiating Irinotecan Arrow, clinicians should assess patient suitability and monitor for potential complications. - Monitor blood counts: perform regular CBCs to detect neutropenia. - Assess gastrointestinal function: watch for severe diarrhea and dehydration. - Evaluate liver function: check hepatic enzymes before and during therapy. - Avoid concurrent myelosuppressive agents: increased risk of bone‑marrow suppression. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan Arrow can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concurrent myelosuppressive chemotherapy: may exacerbate bone‑marrow toxicity. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase Irinotecan exposure and toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce drug levels and effectiveness. - Anticoagulants (e.g., warfarin): potential for increased bleeding risk. - Diuretics: may affect electrolyte balance, requiring monitoring.